Long-term antiplatelet therapy in patients with high risk of stroke

Diseases associated with atherosclerosis occupy a leading place among the causes of death in most countries of the world. Antiplatelet therapy is one of the most eff ective and promising methods of stroke prevention. Long-term use of platelet antiplatelet agents of various pharmaceutical groups in high-risk patients has become a daily clinical practice. As a result of the practical application of modern drug strategies, the life expectancy of stroke survivors is increasing. The average age of patients with cardiovascular pathology is increasing. The majority of patients receiving antiplatelet agents are over 70 years old. The number of patients continuously receiving antiplatelet agents for 10 years or more is already hundreds of thousands. In recent years, clinical guidelines have expanded the indications for the appointment of platelet antiplatelet agents of diff erent pharmaceutical groups. In neurology, clopidogrel, ticagrelor, cilostazol are allowed. However, the choice of the optimal treatment regimen in patients with cerebrovascular pathology often causes diffi culty for doctors. Standard treatment regimens for patients at high risk of stroke are based on the use of acetylsalicylic acid preparations. In some cases, patients receive a combination of antiplatelet agents: aspirin and dipyridamole. The author analyzes the results of 30 years of acetylsalicylic acid use in a patient with a high risk of thrombosis and bleeding. During this period, the patient suff ers a transient ischemic attack, ischemic stroke, hemorrhoidal bleeding and intracranial hemorrhage. The article discusses optimal solutions in choosing an antithrombotic strategy in patients with high risk of stroke on a clinical example. Based on the analysis of current clinical recommendations and scientifi c research, the article formulates the principles of long-term antiplatelet therapy for patients of older age groups with the need for long-term treatment. The main directions of diff erentiated antithrombotic therapy have been determined depending on the suspected pathogenetic subtype of ischemic stroke, the risk of bleeding, age and the expected duration of treatment.

1. Li L., Scott C., Rothwell P. Trends in Stroke Incidence in High-Income Countries in the 21st Century Population-Based Study and Systematic Review. Stroke. 2020;51:1372–1380. DOI: 10.1161/STROKEAHA.119.028484

2. Здравоохранение в России. 2019: Стат.сб./Росстат. М., 2019:170. [Healthcare in Russia. 2019: Stat.sb./ М., 2019:170. (In Russian).

3. Visseren F.L.J., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021;42(34):3227– 3337. DOI: 10.1093/eurheartj/ehab484

4. Suslina Z.A., Tanashyan M.M., Doma shenko M.A. Individualization of antiplatelet therapy in patients with cerebrovascular diseases. Clinical pharmacology and therapy. 2011;5:70–74. (In Russian).

5. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25):2439–2454. DOI: 10.1093/eurheart/ehab309

6. Clinical recommendations for the management of patients with ischemic stroke and transient ischemic attacks / edited by prof. L.V. Stakhovskaya. M., 2017:208. (In Russian).

7. Sumarokov A.B., Shirokov E.A., Buryachkovskaya L.I. Antiplatelet therapy in the prevention of ischemic noncardioembolic stroke. The main provisions of modern recommendations. Moscow, 2015:34. (In Russian).

8. Machinsky P.A., Plotnikova N.A., Ulyankin V.E. et al. Comparative characteristics of the incidence of ischemic and hemorrhagic stroke in Russia. Medical sciences. Pathological anatomy. 2019;2(50):112– 131. (In Russian). DOI: 10.21685/2072-3032-2019-2-11

9. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

10. Li L., Geraghty O., Mehta Z. et al. Age-specifi c risk, severity, timecoruse, and outcome of bleeding on long-timing antiplatelet treatment basded cohort study. Lancet. 2017;29;390(10093):490–499.

11. Bu ryach kovskaya L. I., Lomakin N. V., Sumarokov A. B., Dotsenko Yu.V. The signifi cance of the features of the action of antiplatelet agents for the choice of therapy of a vascular patient. Thrombosis, hemostasis and rheology. 2017;4(72):6–13. (In Russian). DOI:10.25555/THR.2017.4.0803

12. Diener H.C., Sacco R., Yusuf S.; PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Eff ectively Avoiding Second Strokes trial (PRoFESS). Cerebrovasc. Dis. 2007;23:368–80.

13. McHutchison C., Blair G.W., MRCP; Appleton J.P. et al. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline. Systematic Review and Meta-Analysis. Stroke. 2020;51:2374–2385. DOI: 10.1161/STROKEAHA.120.029454

14. Lo makin N.V., Sumarokov A.B., Dotsenko Yu.V. et al. Individual approach to the use of antiplatelet therapy. What to rely on in the decision? Atherothrombosis. 2017;2:70–78. (In Russian).

15. Kennedy J., Ryckborst K., et al. for the FASTER investigators: Fast Assessment of Stroke and Transient Ischemic Attack to prevent Early Recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007;6:961–969.

16. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet. 1996;348:1329–1339.

17. Greving J.P., Diener H., Reitsma J.B. et al. Antiplatelet Therapy After Noncardioembolic Stroke. Stroke. 2019;50(7):1812–1818. DOI: 10.1161/STROKEAHA.118.024497

18. Li Z., Wang Y., Zhao X. et al. Treatment eff ect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. J. Am. Heart Assoc. 2016;5:e003038. DOI: 10/1161/JAHA.115.003038

19. Shirokov E.A., Simonenko V.B., Ovchinnikov Yu.V. Transient ischemic attacks and small strokes: modern therapeutic strategies. Lechasyi vrach. 2020;5:7–11. (In Russian).

20. Wang Y., Meng A., Wang A. et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of Function Carries with Stroke or TIA. N. Engl. J. Med. 2021. DOI: 10/1056/NEJMoa2111749. Online ahead of primt.

21. Uchiyama S., Amarenco P. et al. TIA as acute cerebrovascular syndrome. Front Neurol Neurosci. 2014;33:135–146.

22. Johnston S.C., Amarenco P., Denison H. et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N. Engl. J. Med. 2020;383:207–217.

23. Shaban A., Monlezun D.J., Rincon N. et al. Safety and effi cacy of acute clopidogrel load in patients with moderate and severe ischemic strokes. Stroke Research and Treatment. 2016;2016:8915764. DOI: 10/1155/2016/8915764

24. Balint A., Tornios D., Alaoui O. et al. Network Meta-Analis of Ticagrelor for Stroke prevention in patients at High Risk for Cardiovascular or Cerebrovascular Events. Stroke. 2021;52(9):2809–2816.

25. Chen Z.M., Sandercoch P., Pan H.C. et al. Indication for early aspirin use in acute ischemic stroke. A combined analysis of 40 000 randomized patients from the Chines Acute Stroke Trial and the International Stroke Trial. Stroke. 2000;31:1240–1249.

26. Rothwell P., Algra A., Chen Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016;388(10042):365–375. DOI: 10.1016/S0140-6736(16)30468-8

27. Uchiyama S., Toyoda K., Omae K. et al. Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis. Journal of the American Heart Association. 2021;10(20):19. DOI: 10.1161/JAHA.121.022575

28. Zurrú M., Orzuza C. Epidemiological Aspects of Stroke in Very Old Patients. Cardiovascular and Haematological Disorders-Drug Targets. 2011;11(1):3–5.

29. Niu P.P., Guo Z.N., Jin H. et al. Antiplatelet regimens in the longterm secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ Open. 2016;6: e009013. DOI: 10.1136/bmjopen-2015-009013

30. RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Published Online. 2019. DOI: 10.1016/S0140-6736(19)308402

31. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279:1265– 1272.

32. Waters M., Hoh B., Lynn N. et al. Factors associated with recurrent stroke in the medical group of the SAMMPRIS trial. JAMA Neurol. 2016;73(3):308–315. DOI: 10,1001/jamaneurol.2015.4315